Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

Saved in:
Bibliographic Details
Title: Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
Authors: de Jong VMT; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wang Y; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ter Hoeve ND; Division of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Opdam M; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Stathonikos N; Division of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jóźwiak K; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany., Hauptmann M; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany., Cornelissen S; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Vreuls W; Department of Pathology, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands., Rosenberg EH; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Koop EA; Department of Pathology, Gelre Ziekenhuizen, Apeldoorn, the Netherlands., Varga Z; Departement of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland., van Deurzen CHM; Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands., Mooyaart AL; Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands., Córdoba A; Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Spain., Groen EJ; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands., Willems SM; University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands., Zolota V; Department of Pathology, Rion University Hospital, Patras, Greece., Wesseling J; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Sapino A; Department of Medical Sciences, University of Torino, Torino, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Chmielik E; Tumor Pathology Department, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice, Poland., Ryska A; Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic., Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Voogd AC; Department of Epidemiology, Maastricht University, Maastricht, the Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands., Loi S; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Michiels S; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Wall E; Cancer Center, University Medical Center Utrecht, Utrecht, the Netherlands., Siesling S; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands., van Diest PJ; Division of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Schmidt MK; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands., Kok M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Dackus GMHE; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Salgado R; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium., Linn SC; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Jul 20; Vol. 40 (21), pp. 2361-2374. Date of Electronic Publication: 2022 Mar 30.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.21.01536